1. Home
  2. PIII vs CTXR Comparison

PIII vs CTXR Comparison

Compare PIII & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo P3 Health Partners Inc.

PIII

P3 Health Partners Inc.

HOLD

Current Price

$1.63

Market Cap

15.6M

Sector

Health Care

ML Signal

HOLD

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

SELL

Current Price

$0.51

Market Cap

13.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PIII
CTXR
Founded
2015
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.6M
13.4M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
PIII
CTXR
Price
$1.63
$0.51
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $7.75
N/A
AVG Volume (30 Days)
32.6K
★ 253.3K
Earning Date
11-09-2026
12-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 43.38
EPS
★ N/A
N/A
Revenue
★ $1,459,080,000.00
N/A
Revenue This Year
$7.84
N/A
Revenue Next Year
$7.13
$104.18
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.52
$0.37
52 Week High
$16.89
$1.54

Technical Indicators

Market Signals
Indicator
PIII
CTXR
Relative Strength Index (RSI) 21.10 48.05
Support Level N/A $0.47
Resistance Level $3.07 $0.63
Average True Range (ATR) 0.39 0.06
MACD -0.08 -0.00
Stochastic Oscillator 1.41 22.42

Price Performance

Historical Comparison
PIII
CTXR

About PIII P3 Health Partners Inc.

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: